On Tuesday, Daiichi Sankyo and Merck announced that the jointly developed deruxtecan achieved its primary objective in a late-stage study for certain lung cancer patients. Compared to patients receiving chemotherapy, deruxtecan can significantly extend the lifespan of patients with cancer without progression. This therapy is one of the three antibody-drug conjugates (ADCs) included in the $22 billion joint development and commercialization agreement signed by Merck and Daiichi Sankyo last year. The two companies plan to present the trial data at an upcoming medical conference and share it with global regulatory institutions to discuss next steps.